TCIM
SGMO

TIAA CREF Investment Management’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

TIAA CREF Investment Management’s Portfolio SGMO Stock Details SGMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		$4.74M Sell
496,753
-41,118
-8% -$420K ﹤0.01% 1484
2018
Q4 		$6.17M Sell
537,871
-19,955
-4% -$248K ﹤0.01% 1242
2018
Q3 		$9.46M Buy
557,826
+45,520
+9% +$692K 0.01% 1134
2018
Q2 		$7.28M Sell
512,306
-72,232
-12% -$1.2M ﹤0.01% 1347
2018
Q1 		$11.1M Sell
584,538
-298,844
-34% -$6.39M 0.01% 1054
2017
Q4 		$14.5M Buy
883,382
+164,900
+23% +$2.45M 0.01% 930
2017
Q3 		$10.8M Buy
718,482
+511,919
+248% +$5.66M 0.01% 1106
2017
Q2 		$1.82M Sell
206,563
-73,549
-26% -$472K ﹤0.01% 2233
2017
Q1 		$1.46M Sell
280,112
-7,429
-3% -$29.8K ﹤0.01% 2320
2016
Q4 		$877K Sell
287,541
-11,780
-4% -$42.9K ﹤0.01% 2614
2016
Q3 		$1.39K Sell
299,321
-17,530
-6% -$89.2K ﹤0.01% 2365
2016
Q2 		$1.83M Buy
316,851
+5,304
+2% +$33.8K ﹤0.01% 2172
2016
Q1 		$1.89M Sell
311,547
-7,844
-2% -$47.1K ﹤0.01% 2108
2015
Q4 		$2.92M Hold
319,391
– – ﹤0.01% 1923
2015
Q3 		$1.8M Sell
319,391
-15,005
-4% -$124K ﹤0.01% 2209
2015
Q2 		$3.71M Sell
334,396
-30,672
-8% -$395K ﹤0.01% 1900
2015
Q1 		$5.72M Buy
365,068
+1,574
+0.4% +$24.4K ﹤0.01% 1540
2014
Q4 		$5.53M Sell
363,494
-15,094
-4% -$183K ﹤0.01% 1564
2014
Q3 		$4.08M Sell
378,588
-4,736
-1% -$61.9K ﹤0.01% 1758
2014
Q2 		$5.85M Buy
383,324
+26,300
+7% +$378K ﹤0.01% 1562
2014
Q1 		$6.46M Buy
357,024
+32,492
+10% +$626K ﹤0.01% 1429
2013
Q4 		$4.51M Buy
324,532
+18,480
+6% +$213K ﹤0.01% 1706
2013
Q3 		$3.21M Sell
306,052
-7,503
-2% -$74.5K ﹤0.01% 1911
2013
Q2 		$2.45M Buy
+313,555
New +$2.74M ﹤0.01% 2037

Other funds holding SGMO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

TIAA CREF Investment Management's SGMO Position: Q1 2019 in Review

TIAA CREF Investment Management reduced its SANGAMO THERAPEUTICS INC (SGMO) stake by 7.6% in Q1 2019, selling an estimated $420K and leaving 496,753 shares worth $4.74M. The position accounts for ﹤0.01% of the portfolio, ranked #1484.

TIAA CREF Investment Management first reported a position in SGMO in Q2 2013 and has held it in 24 quarters since. The position peaked at $14.5M in Q4 2017. 187 funds tracked by Wall St. Rank hold SGMO as of Q1 2019.

  • TIAA CREF Investment Management held 496,753 shares of SANGAMO THERAPEUTICS INC worth $4.74M as of Q1 2019.
  • TIAA CREF Investment Management sold 41,118 SANGAMO THERAPEUTICS INC shares in Q1 2019, an estimated $420K.
  • SANGAMO THERAPEUTICS INC made up ﹤0.01% of TIAA CREF Investment Management's portfolio in Q1 2019, its #1484 holding.
  • TIAA CREF Investment Management first reported a position in SANGAMO THERAPEUTICS INC in Q2 2013 and has held it in 24 quarters since.
  • TIAA CREF Investment Management's SANGAMO THERAPEUTICS INC position peaked at $14.5M in Q4 2017.
  • 187 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q1 2019.

Based on TIAA CREF Investment Management's 13F filing for Q1 2019, filed 14 May 2019.